William Lockwood
William Lockwood
Senior Scientist, British Columbia Cancer Agency - Associate Professor, University of British
Verified email at - Homepage
Cited by
Cited by
PIK3CA mutations and copy number gains in human lung cancers
H Yamamoto, H Shigematsu, M Nomura, WW Lockwood, M Sato, ...
Cancer research 68 (17), 6913-6921, 2008
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
WW Lockwood, K Zejnullahu, JE Bradner, H Varmus
Proceedings of the National Academy of Sciences 109 (47), 19408-19413, 2012
Lung cancer cell lines as tools for biomedical discovery and research
AF Gazdar, L Girard, WW Lockwood, WL Lam, JD Minna
Journal of the National Cancer Institute 102 (17), 1310-1321, 2010
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells
J Soh, N Okumura, WW Lockwood, H Yamamoto, H Shigematsu, ...
PloS one 4 (10), e7464, 2009
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
J Gandhi, J Zhang, Y Xie, J Soh, H Shigematsu, W Zhang, H Yamamoto, ...
PloS one 4 (2), e4576, 2009
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
JKM Lim, A Delaidelli, SW Minaker, HF Zhang, M Colovic, H Yang, ...
Proceedings of the National Academy of Sciences 116 (19), 9433-9442, 2019
TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer
DT Starczynowski, WW Lockwood, S Deléhouzée, R Chari, J Wegrzyn, ...
The Journal of clinical investigation 121 (10), 4095-4105, 2011
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
EA Marshall, KW Ng, SHY Kung, EM Conway, VD Martinez, EC Halvorsen, ...
Molecular cancer 15, 1-15, 2016
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models
A Taguchi, K Politi, SJ Pitteri, WW Lockwood, VM Faça, K Kelly-Spratt, ...
Cancer cell 20 (3), 289-299, 2011
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
AM Unni, WW Lockwood, K Zejnullahu, SQ Lee-Lin, H Varmus
Elife 4, e06907, 2015
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ...
Cancer discovery 8 (6), 686-695, 2018
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
T Kubo, H Yamamoto, WW Lockwood, I Valencia, J Soh, M Peyton, M Jida, ...
International journal of cancer 124 (8), 1778-1784, 2009
Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
R Somwar, H Erdjument-Bromage, E Larsson, D Shum, WW Lockwood, ...
Proceedings of the National Academy of Sciences 108 (39), 16375-16380, 2011
Recent advances in array comparative genomic hybridization technologies and their applications in human genetics
WW Lockwood, R Chari, B Chi, WL Lam
European Journal of Human Genetics 14 (2), 139-148, 2006
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Y Xue, B Meehan, Z Fu, XQD Wang, PO Fiset, R Rieker, C Levins, T Kong, ...
Nature communications 10 (1), 557, 2019
High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGH
C Garnis, WW Lockwood, E Vucic, Y Ge, L Girard, JD Minna, AF Gazdar, ...
International Journal of Cancer 118 (6), 1556-1564, 2006
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers
WW Lockwood, R Chari, BP Coe, L Girard, C Macaulay, S Lam, ...
Oncogene 27 (33), 4615-4624, 2008
Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma
WW Lockwood, R Chari, BP Coe, KL Thu, C Garnis, CA Malloff, ...
PLoS medicine 7 (7), e1000315, 2010
Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ...
Clinical Cancer Research 25 (4), 1248-1260, 2019
Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma
L Lin, AJ Bass, WW Lockwood, Z Wang, AL Silvers, DG Thomas, ...
Proceedings of the National Academy of Sciences 109 (11), 4251-4256, 2012
The system can't perform the operation now. Try again later.
Articles 1–20